Study With Various Immunotherapy Treatments in Participants With Lung Cancer

NCT05676931 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

400

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Non-Small Cell Lung Cancer

Interventions

DRUG: Domvanalimab
DRUG: Quemliclustat
DRUG: Zimberelimab
DRUG: Docetaxel
DRUG: Platinum-Based Doublet

Sponsor

Gilead Sciences

Collaborators

[object Object]